Early immunotherapy is highly effective in IgG1/IgG4 positive IgLON5 disease
J Neurol
.
2020 Jul;267(7):2151-2153.
doi: 10.1007/s00415-020-09924-y.
Epub 2020 May 22.
Authors
Thomas Grüter
1
,
Volker Behrendt
1
,
Corinna I Bien
2
,
Ralf Gold
1
,
Ilya Ayzenberg
3
4
Affiliations
1
Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstr. 56, 44791, Bochum, Germany.
2
Laboratory Krone, Siemensstr. 40, 32105, Bad Salzuflen, Germany.
3
Department of Neurology, St. Josef Hospital, Ruhr University Bochum, Gudrunstr. 56, 44791, Bochum, Germany. ilya_ayzenberg@yahoo.com.
4
Department of Neurology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia. ilya_ayzenberg@yahoo.com.
PMID:
32444985
PMCID:
PMC7320942
DOI:
10.1007/s00415-020-09924-y
No abstract available
Publication types
Case Reports
Letter
MeSH terms
Cell Adhesion Molecules, Neuronal
Humans
Immunoglobulin G*
Immunologic Factors / therapeutic use
Immunotherapy*
Substances
Cell Adhesion Molecules, Neuronal
IgLON5 protein, human
Immunoglobulin G
Immunologic Factors